Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 5 of the 8 sources its claims cite were checked for support.
Abstract
Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is the second leading cause of cancer mortality worldwide. Fibroblast Growth Factor 19 (FGF19) is one of the most frequently amplified genes in HCC patients. Moreover, mice expressing an FGF19 transgene have been shown to develop HCC. However, the downstream signalling pathways that mediate FGF19-dependent tumorigenesis remain to be deciphered. Here we show that FGF19 triggers a previously unsuspected, non-cell-autonomous program to activate STAT3 signalling in hepatocytes through IL-6 produced in the liver microenvironment. We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact. Collectively, these data reveal a key role for the IL-6/STAT3 axis in potentiating FGF19-driven HCC in mice, a finding which may have translational relevance in HCC pathogenesis.
Overview
CoChat Summary
TL;DR
FGF19-driven hepatocellular carcinogenesis in mice requires non-cell-autonomous IL-6/STAT3 signaling: FGF19 induces IL-6 from liver innate immune cells, which activates STAT3 in hepatocytes to promote tumorigenesis. Blocking this axis prevents FGF19-induced HCC while preserving FGF19’s bile acid, glucose, and energy metabolic functions.
Key findings
- Hepatocyte-specific Stat3 deletion blocked FGF19-induced HCC: ∼90% of Stat3f/f mice developed hepatocellular carcinomas 12 months after AAV-FGF19, whereas tumor incidence, multiplicity, and size were markedly reduced in Stat3ΔHep mice; serum FGF19 was 292±29 ng ml−1 in Stat3f/f and 275±47 ng ml−1 in Stat3ΔHep mice.
- Stat3 was dispensable for FGF19 metabolic actions: FGF19 reduced Cyp7a1 mRNA by 77% in Stat3f/f and 87% in Stat3ΔHep mice, and Cyp8b1 by 95% and 88%, respectively; body weight, glucose, body composition, and steatosis effects were similar.
- FGF19 activated STAT3 non-cell-autonomously via IL-6: FGF19 induced hepatic pSTAT3Y705 in vivo but not in isolated mouse or human hepatocytes; IL-6 mRNA increased in FGF19-treated db/db mice, and IL-6 was produced mainly by CD45+ myeloid cells including Kupffer cells, neutrophils, and NK cells.
- Genetic or pharmacological blockade of IL-6/STAT3 abolished FGF19-driven HCC: Il6 deletion reduced tumor multiplicity, size, and glutamine synthetase-positive tumor area; SOCS3 co-expression, tofacitinib, or anti-IL-6 treatment reduced or abolished tumors without altering FGF19 metabolic effects. In human data, FGF19 amplification occurred in 7% of HCCs, and FGF19 mRNA was elevated in 10/83 FFPE HCC specimens (12%), all co-overexpressing BIRC5.
Methods
- Mouse models: AAV-FGF19 delivery in Stat3f/f, hepatocyte-specific Stat3ΔHep, Il6−/−, db/db, and Mdr2−/− mice; primary mouse and human hepatocytes; immune cell depletion with clodronate liposomes or antibodies.
- Main assays: immunoblotting for pSTAT3/pERK, qRT-PCR, immunohistochemistry, flow cytometry, BrdU incorporation, ELISA for FGF19/insulin/liver enzymes/bile acids, and tumor assessment by gross and histological analysis.
- Human data and statistics: TCGA and GTEx bioinformatics, RNAscope in situ hybridization and qRT-PCR on human HCC samples; unpaired t-test, one-way ANOVA with Dunnett’s post-test, Spearman correlation, and Kaplan–Meier log-rank analysis.
Limitations
- Stated: the extent to which mouse findings translate to human HCC remains unclear; other mechanisms of FGF19 tumorigenesis are not excluded; the precise mechanism by which FGF19 promotes IL-6 secretion from innate immune cells remains to be determined; direct effects of IL-6 on stem-marker-enriched hepatocyte subpopulations were not observed and require further study.
- Evident: investigators were not blinded during the studies; in vivo experiments used cohorts of 3–9 mice per group; male mice were used unless otherwise specified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
4 Valid · 0 Not valid · 0 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In defining a central role for STAT3 in FGF19-driven hepatocarcinogenesis, the data presented in this report extend previous findings on the causal role played by STAT3 in hepatocellular tumorigenesis4445, and suggest that STAT3 may serve as a common signalling node in the development of HCC associated with diverse etiologies, including viral infection, and metabolic and hormonal dysregulation.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Discussion
What the sources say
- Supportedcites [44] He, G. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286–297 (2010). source
The citation is attached to the preceding statement about STAT3’s causal role in hepatocellular tumorigenesis, not to the citing authors’ subsequent suggestion about diverse etiologies. In Results (‘STAT3 activity is required for HCC formation and growth’), hepatocyte-specific STAT3-deficient mice had markedly fewer and smaller DEN-induced tumors, supporting that attributed finding. (LLM, conf=0.92)
- Supportedcites [45] Bard-Chapeau, E. A. et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629–639 (2011). source
The Results section reports that Stat3 deletion abolished the increase in HCC development caused by Shp2 deletion, supporting the cited claim of a causal role in hepatocellular tumorigenesis. The Discussion also notes that Stat3 was not required for HCC development in the DEN-induced model. The broader proposal about diverse etiologies is the citing authors’ own suggestion, not a finding attributed to this source; page numbers were not supplied. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, FGF19 administration failed to induce hepatic expression of a panel of growth factors and cytokines associated with increased pSTAT3 signalling, including epidermal growth factor (EGF)31, IL-10 (ref. 32), IL-21 (ref. 33), IL-22 (ref. 34) and IL-31 (ref. 35)”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Results > Secreted factor(s) mediating activation of STAT3 by FGF19
What the sources say
- Not checked — no full text of the sourcecites [31] Zhong, Z., Wen, Z. & Darnell, J. E. Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95–98 (1994). source
- Supportedcites [32] Weber-Nordt, R. M. et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271, 27954–27961 (1996). source
Reference 32 is attached to IL-10 as an example of a cytokine associated with increased pSTAT3 signalling, not to the citing authors’ finding about FGF19 or hepatic expression. The Results section reports that adding IL-10 generated tyrosine-phosphorylated Stat3; it does not need to establish the separate FGF19 finding. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [33] Brenne, A. T. et al. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99, 3756–3762 (2002). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Notably, IL-6 appears to be an essential factor common to the induction of HCC by a variety of stimuli, including chemical61, obesity62 and FGF19.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Discussion
What the sources say
- Not checked — no full text of the sourcecites [61] Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121–124 (2007). source
- Supportedcites [62] Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197–208 (2010). source
Citation 62 is attached to obesity, not to chemical induction or FGF19. In Results, “Enhanced IL-6 production is required for obesity-induced tumor promotion,” IL6-deficient male mice showed no significant increase in tumor load with a high-fat diet, supporting the attributed role of IL-6 in obesity-promoted HCC in this mouse model. (LLM, conf=0.91)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact.”
- Also stated in: § Stat3 is essential for FGF19-induced hepatocarcinogenesis · boosted
“Collectively, we conclude from these observations that hepatocellular ablation of Stat3 blocks the initiation and progression of FGF19-dependent HCC formation.”
- Also stated in: § Discussion · plain
“Our results showed that hepatocellular STAT3 is a critical effector in FGF19-induced HCC formation.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Stat3 is essential for FGF19-induced hepatocarcinogenesis · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact.”
- Also stated in: § Stat3 is dispensable for FGF19-regulated metabolism · plain
“Therefore, while critical for FGF19-dependent HCC formation, hepatocellular Stat3 is not required for FGF19 to regulate bile acid biosynthesis or restore metabolic homoeostasis.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Stat3 is dispensable for FGF19-regulated metabolism · plain
46 more claims
Create a free account to see all 79 claims and every source verdict.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 1
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been found that the tumorigenic effect of FGF19 is mediated by the release of interleukin 6 (IL6) by Kupffer cells that activate the signal transducer and activator of transcription (STAT3) pathway in hepatocytes [261].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [261]
In the citing paper
“NGM282 is a nontumorigenic analogue of FGF19 being evaluated for the treatment of PBC.”
From NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) · cites this paper as [16]
In the citing paper
“In contrast, NGM282 does not activate STAT3, a signaling pathway essential for FGF19‐mediated hepatocarcinogenesis.16”
From NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) · cites this paper as [16]
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Cited by
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Pierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425
Self-citationLiver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280
Self-citation
Metadata
- Authors
- Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L.
- Affiliations
- NGM Biopharmaceuticals (United States) (US)
- Corresponding author
- Ling, Lei
- Venue
- Nature Communications
- Published
- 2017-05-16
- Volume
- 8
- Issue
- 1
- Pages
- 15433-15433
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5440856
- OpenAlex
- W2616559215
- Cited by
- 123
- References
- 62
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 12 · 2021: 19 · 2020: 22 · 2019: 16 · 2018: 20 · 2017: 5
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NGM Biopharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- FGF19, hepatocellular carcinoma, IL-6/STAT3 signaling, non-cell-autonomous signaling, liver microenvironment, JAK inhibitors, anti-IL-6 antibody, bile acid metabolism, glucose metabolism, energy metabolism, hepatocarcinogenesis
- MeSH terms
- Dependovirus, Animals, Bile Acids and Salts, Body Composition, Energy Metabolism, Female, Fibroblast Growth Factors, Glucose, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Signal Transduction, Interleukin-6, Gene Expression Regulation, Neoplastic, Gene Deletion, Transgenes, Computational Biology, Gene Expression Profiling, STAT3 Transcription Factor, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-23, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-23 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. https://app.cochat.ai/papers/10.1038/ncomms15433
- The paper
- Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017). Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nature Communications. https://doi.org/10.1038/ncomms15433
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.